Recombinant hGM-CSF herpes simplex virus (OrienGene Biotechnology)

重组人GM-CSF单纯疱疹病毒（北京奥源和力）

Report date: 2022/05/18 17:41:50

Base Information

Drug NameRecombinant hGM-CSF herpes simplex virus (OrienGene Biotechnology)
Drug Alias Name重组人GM-CSF单纯疱疹病毒注射液rhGM-CSF Herpes Simplex VirusrhGM-CSF HSV重组人GM-CSF单纯疱疹病毒Recombinant hGM-CSF HSV +[6] 
ClassificationBiologics > Oncolytic virusCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Herpes simplex virus vector
Mechanisms of ActionColony stimulating factor stimulants
TargetsColony stimulating factor
Therapy Area/IndicationsSkin MelanomaLung NeoplasmsPancreatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesOriengene Biotechnology Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOriengene Biotechnology Ltd
Inactive CompaniesN/A
Active IndicationsMelanoma
Inactive IndicationsSkin MelanomaLung NeoplasmsPancreatic Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A